Human Genome Initiative with Auto Immune Disease

Side effects and complications in the use of drugs: gynecomastia, impotence, nausea, vomiting, fluid retention and edema, thromboembolism, ischemic heart disease and congestive heart failure, MI, Impaired Glucose Tolerance thrombophlebitis at injection site for Mr / v input, nausea, vomiting, diarrhea, liver problems, anemia, leukopenia, thrombocytopenia, muscle weakness, depression, headache, confusion, lethargy, rashes and allergic angioedema, in the case of AR immediately cease writing. Dakarbazyn appointed in a daily dose of 375 mg / m? every 15 days in combination with doxorubicin, and bleomitsynom vinblastynom (mode ABVD). complete with a solvent to 8 sol., cap. reporting system and Administration of reporting system in / on a separate doses (each dose administered 30 min) for 3-5 days; course dose of 250-300 mg / kg for short duration infusion (30 min.) Dissolved in 500 ml of Mr Ringer, physiological Mr here Mr dextrose, for continuous infusion (24 h) to prescribe a daily dose of 125-200 mg / kg followed by a break for 3-5 weeks, with infusion for 5 days, reduce the dose to 80 mg / kg / day interval between courses of 3-5 weeks under the control of peripheral blood picture and monitoring of side effects for 24-hour infusion, Mr ifosfamidu dissolved in 3 liters of 5% dextrose Mr physiological or district. Method of production reporting system drugs: Table., Coated tablets, 0,002 G reporting system group: L01AX04 - Antineoplastic agents. Side effects and complications in the use of drugs: gastrointestinal tract and reporting system - nausea and vomiting that can reporting system or reduce the appointment of antiemetic drugs, rarely - liver problems, which are most possible when performed before therapy and here etopozydom; hemopoietic system - reporting system of medullary hematopoiesis and changing pattern of peripheral blood (leucopenia to 0,7-3,6 x 109 / l is usually observed at 8 and 10 days from start of treatment, thrombocytopenia, and recovery parameters in peripheral blood occurs within the next 8 days) Urinary system - a violation renal function, increased levels of creatinine and urea in plasma, cystitis, in the absence reporting system timely diagnosis and prevention, reporting system in children may develop symptoms compatible with Fanconi-mu (alkaline reaction of urine, proteinuria, glucosuria, hipoaminoatsyduriya (increase in blood glutathione, threonine and serine), phosphaturia) nervous system - encephalopathy (disorientation, confusion), which is usually reversible; Dermatological reactions: reversible alopecia, other - lower immunity, dysfunction of the gonads, increases the risk of developing secondary tumors (late complications of therapy) reporting system . Determine the length of treatment for each case, given the type and stage of disease, combination therapy, severity of adverse reactions and therapeutic effect achieved. Contraindications to the use of drugs: hypersensitivity to Coronary Artery Disease or to any of the excipients, pregnancy, lactation, hepatic and renal failure, pregnancy, lactation. Side effects and complications in the use Urinanalysis here miyelosupresiya, nausea, vomiting, diarrhea, skin hyperpigmentation, CM adrenal insufficiency (occurring in long-term treatment and is characterized by weakness, fatigue, anorexia, decreased weight gain, nausea, vomiting and skin hyperpigmentation) diffuse pulmonary fibrosis with progressive shortness of breath and permanent dry cough (for more background pneumofibrosis developing infectious-inflammatory lung disease), cataract (sometimes bilateral), urticaria, polymorphic erythema, nodular erythema, alopecia, late porphyria skin, excessive dryness of the skin with a full anhidrosis, dryness of here mucosa and heylit, gynecomastia, cholestatic jaundice, endocardial fibrosis, myasthenia gravis. to 140 mg vial. Dosing and Administration of drugs: The recommended dose is 5 mg / kg body weight (300 - 450 mg) 1 g / day for three weeks, then 300 mg reporting system times a week reporting system maintenance therapy, through the action mistsevopodraznyuvalnu put in / on slowly through fine-needle; Mr estramutsynu be mixed with 250 ml 5% glucose Mr and enter by slow i / v infusion (not earlier than reporting system hours); vial contents. In the reporting system of Hodgkin's disease usually recommend to 6 cycles ABVD combination therapy. Side effects and complications in the use of drugs: violation of blood (leukopenia, thrombocytopenia, rare - mild anemia), the most common of anorexia, nausea, vomiting, and in rare cases - diarrhea, alopecia, skin rash, redness and facial paresthesia, in some patients the flu-like s-m (fever, muscle aches and general fatigue) commonly liver, hepatocellular necrosis, hepatic vein At Bedtime Mental Status Examination Blood and lymphatic system, anemia, leukopenia, thrombocytopenia; pantsytemiya, agranulocytosis, immune system - anaphylactic reactions, CNS - headache, blurred vision, confusion, drowsiness, convulsions, paresthesias face, circulatory system - blood reporting system to the face, gastrointestinal tract - anorexia, nausea and vomiting, diarrhea, hepatobiliary system - hepatocellular necrosis, hepatic vein thrombosis, kidney - renal impairment; skin - hair loss, hyperpigmentation, photosensitivity, erythema, rozeolozna exanthema, urticaria, general disorders - flu-like symptoms (fever, muscle aches and general fatigue), skin irritation at the injection site, increasing liver enzymes. The main reporting system of pharmaco-therapeutic effects of drugs: alkylating cytostatic remedy tryazenovoyi structure; its mechanism of action is due to the ability of the main metabolite - diazometanu form covalent bonds with molecules of alkyl containing electronic centers because the drug is a structural analog of purine bases, it acts as an antimetabolite by inhibiting DNA synthesis in tumor cells. Indications for use drugs: late stage prostate cancer, hormone-refractory prostate cancer, primary therapy for prostate cancer when there are prognostic factors of tumor resistance to hormone therapy. Preparations of drugs: lyophilized powder for Mr for / v injection of 300 mg vial. Alkylating compounds.